What can we learn from zebrafish about human blood disorders?
New Rochelle, NY, May 6, 2016–Genetic regulation of the various types of blood cells in zebrafish and humans is highly similar, making it relatively easy and cost-effective to perform genetic, chemical, imaging and other molecular studies on this invaluable model organism to study normal hematopoetic development in humans as well as blood disorders and malignancies, as described in a Review article in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free for download on the Human Gene Therapy website until June 6, 2016.
Serine Avagyan and Leonard Zon, Boston Children's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School (Boston, MA) and Harvard University (Cambridge, MA), examine the major discoveries that have helped define molecular control of hematopoiesis in vertebrates, highlighting the knowledge gained from studies of zebrafish.
In the article "Fish to Learn: Insights into Blood Development and Blood Disorders from Zebrafish Hematopoiesis," the authors discuss the unique attributes of zebrafish that make it useful as a model system for performing large-scale forward genetic screens to silence or over-express target genes to determine their function, chemical screens, live imaging of blood system development at the single cell level, and modeling of hematopoetic disorders and malignancies by inserting human genes to create transgenic zebrafish.
This article is part of a Festschrift in honor of George Stamatoyannopoulous, MD, DrSci, Professor of Medicine and Genome Sciences, and Director, Markey Molecular Medicine Center, University of Washington, Seattle.
"Zebrafish have proven to be an extremely powerful model for understanding developmental biology, including the developmental biology of blood-forming tissues," says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA. "The review from the Zon laboratory beautifully illustrates how critical such studies have been to broader progress in biomedicine, as has long been envisioned by pioneers of molecular medicine like Dr. George Stamatoyannopoulous."
About the Journal
Human Gene Therapy, the Official Journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Led by Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its companion journals, Human Gene Therapy Methods, published bimonthly, focuses on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development, published quarterly, features data relevant to the regulatory review and commercial development of cell and gene therapy products. Tables of contents for all three publications and a free sample issue may be viewed on the Human Gene Therapy website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Nucleic Acid Therapeutics, Tissue Engineering, Stem Cells and Development, and Cellular Reprogramming. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.